Article
Cover
RJPS Journal Cover Page

RJPS Vol No: 14 Issue No: 3 eISSN: pISSN:2249-2208

Article Submission Guidelines

Dear Authors,
We invite you to watch this comprehensive video guide on the process of submitting your article online. This video will provide you with step-by-step instructions to ensure a smooth and successful submission.
Thank you for your attention and cooperation.

Original Article
Shubham B Patil1, Anand S Ammanage2, Amolkumar A Kempwade*,3, Umeshkumar D Patel4, Anagha Patil5,

1Department of Pharmaceutics, KLE College of Pharmacy, Nipani, Karnataka, India.

2Department of Pharmaceutics, KLE College of Pharmacy, Nipani, Karnataka, India.

3Dr. Amolkumar A. Kempwade, Department of Pharmaceutics, KLE College of Pharmacy, Nipani, Karnataka, India.

4Department of Pharmaceutics, KLE College of Pharmacy, Nipani, Karnataka, India.

5Department of Pharmaceutics, KLE College of Pharmacy, Nipani, Karnataka, India.

*Corresponding Author:

Dr. Amolkumar A. Kempwade, Department of Pharmaceutics, KLE College of Pharmacy, Nipani, Karnataka, India., Email: kempwadeamol@rediffmail.com
Received Date: 2023-02-06,
Accepted Date: 2023-05-25,
Published Date: 2023-06-30
Year: 2023, Volume: 13, Issue: 2, Page no. 48-53, DOI: 10.26463/rjps.13_2_7
Views: 832, Downloads: 51
Licensing Information:
CC BY NC 4.0 ICON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0.
Abstract

Aim: The present work aimed to develop and evaluate Paroxetine HCl thermoreversible and mucoadhesive in situ intranasal gel.

Methodology: Carbopol 934P and poloxamer 407 have been utilized for the development of Paroxetine HCl thermoreversible and mucoadhesive in situ intranasal gel. The cold technique was used to formulate in situ intranasal gel. Evaluation of physico-chemical parameters, clarity, viscosity, pH, drug content, and mucoadhesive strength was performed for intranasal in situ gel. In vitro drug release studies, ex-vivo permeation studies, and stability studies were conducted for all the formulations.

Results: A 19% w/v of poloxamer 407 solution showed phase transition temperature at physiologic conditions (32–34o C). The mucoadhesive strength was found to be below 7,000 dynes/cm2 till 0.4% w/v concentration of carbopol 934P. Gelation temperature of formulation A4 was found to be satisfactory. Mucoadhesive strength in all the formulations was shown to be above 4,000 dynes/cm2 . The gelation time and gel melting temperature of all the formulations showed uniformity. In vitro drug release was in the range of 54.8% to 83.22% in 8 h. Ex vivo drug release of the optimized A4 formulation was found to be 82.3% in 8h. All the formulations were found stable except A5.

Conclusion: Based on the results of in vitro and ex vivo studies, the A4 formulation was found to be optimum. Thus, the present work concluded that Paroxetine HCl thermoreversible in situ intranasal gel is safe and effective for treating depression.

<p style="text-align: justify;"><strong>Aim: </strong>The present work aimed to develop and evaluate Paroxetine HCl thermoreversible and mucoadhesive <em>in situ</em> intranasal gel.</p> <p style="text-align: justify;"><strong>Methodology:</strong> Carbopol 934P and poloxamer 407 have been utilized for the development of Paroxetine HCl thermoreversible and mucoadhesive <em>in situ</em> intranasal gel. The cold technique was used to formulate <em>in situ</em> intranasal gel. Evaluation of physico-chemical parameters, clarity, viscosity, pH, drug content, and mucoadhesive strength was performed for intranasal <em>in situ</em> gel. <em>In vitro</em> drug release studies, <em>ex-vivo</em> permeation studies, and stability studies were conducted for all the formulations.</p> <p style="text-align: justify;"><strong>Results: </strong>A 19% w/v of poloxamer 407 solution showed phase transition temperature at physiologic conditions (32&ndash;34o C). The mucoadhesive strength was found to be below 7,000 dynes/cm2 till 0.4% w/v concentration of carbopol 934P. Gelation temperature of formulation A4 was found to be satisfactory. Mucoadhesive strength in all the formulations was shown to be above 4,000 dynes/cm2 . The gelation time and gel melting temperature of all the formulations showed uniformity. In vitro drug release was in the range of 54.8% to 83.22% in 8 h. <em>Ex vivo</em> drug release of the optimized A4 formulation was found to be 82.3% in 8h. All the formulations were found stable except A5.</p> <p style="text-align: justify;"><strong>Conclusion: </strong>Based on the results of <em>in vitro </em>and <em>ex vivo </em>studies, the A4 formulation was found to be optimum. Thus, the present work concluded that Paroxetine HCl thermoreversible <em>in situ </em>intranasal gel is safe and effective for treating depression.</p>
Keywords
Paroxetine HCl, Carbopol 934P, Poloxamer 407, In situ intranasal gel
Downloads
  • 1
    FullTextPDF
Article
Introduction

Depression is one of the leading causes of disability worldwide and leads to a significant health burden. It was reported that within a span of ten years, from 2005 to 2015, the number of cases of depression increased by 18%. It affects 322 million people worldwide, affecting nearly 4% of the population.1

Depression is a condition of detestation and low mood; such activity can affect a person's feelings, thoughts, behavior, physical well-being, and circadian rhythm.2

Antidepressants are psychotropic drugs that are available in a wide range of dosages to treat mental conditions such as obsessive-compulsive disorder, clinical depression, anxiety disorders like panic, post-traumatic stress, social and serious phobias. Presently in US, the three top most used drug classes are antidepressants.3

There are two mainstays for treating depression: pharmacotherapy and psychotherapy. Selective serotonin reuptake inhibitors (SSRIs) are second-generation and first-line antidepressant drugs used to manage major depression.4

Paroxetine belongs to the SSRIs class of antidepressant agents. It is a potent and selective neuronal serotonin reuptake inhibitor, which has a little affinity towards β-adrenergic, muscarinic (α1, α2), dopamine (D2, 5-HT1, 5- and histamine (H1) receptors. Paroxetine expresses its action at the synaptic receptor and increases 5-HT in the CNS by inhibiting the reuptake of serotonin and boosting serotonergic neurotransmission by decreasing the production of a neurotransmitter. The dose of Paroxetine is 10-60 mg per day orally, with a plasma half-life of about 21 h, with <50% oral bioavailability due to hepatic first-pass metabolism.5

There is a need to develop an alternative drug delivery system for Paroxetine to bypass hepatic first-pass metabolism and increase bioavailability.

The intranasal route is one of the alternative routes for drugs that undergo extremely rapid first-pass metabolism. Delivery of the drug to the brain by this route is more advantageous than directly delivering the drug to the brain via the olfactory route.6,7

The problem associated with the nasal route is nasolacrimal drainage. The dose instilled into the nose ultimately enters the pharynx and follows the same fate as that of the oral route. To tackle this problem, nowadays, in situ gelling systems have been developed wherein formulation remains in the sol phase at normal temperature but turns into gel when instilled into the nose due to higher temperature in the nasal cavity.

Thus, in the present work, an attempt was made to formulate a thermoreversible gel that provides sufficient viscosity and mucoadhesive strength to improve the residence time of the formulation in the nasal cavity. Further addition of mucoadhesive polymers increases the residence time of the formulation in the nose. The synergistic effect of these helps improve the performance of the formulation.

Materials and Methods

Paroxetine hydrochloride, Carbopol 934, and Poloxamer 407 were procured from Yarrow Chem. Products, Mumbai, and all other solvents and chemicals were obtained from authenticated sources.

Gelation temperature determination8

A visual inspection method was adopted to determine the gelation temperature. Poloxamer 407 solutions 15-20% w/v were prepared and measured. About 10 mL of each solution was kept on a hot plate magnetic stirrer, heating at 32–34º C. Gelation or transition temperature was noticed at 32-34º C, where rotation of the magnetic bead stopped due to gel formation. Different concentrations, i.e., 0.1–0.5% w/v of carbopol 934P in poloxamer 407 solution, at which gelation took place were used for further study.

Formulation of Paroxetine HCl in situ intranasal gel9

The formulation of Paroxetine HCl in situ intranasal gel was prepared by cold technique. Various batches of A1 to A5 were formulated as presented in Table 1. Carbopol 934P was dispersed completely in cold water to get solutions ranging from 0.1 to 0.5% w/v of Carbopol 934P. Poloxamer 407 was added to the above solutions in such a way that the final concentration of poloxamer in solution becomes 19% w/v. These gel systems were placed in cold conditions (4-8º C) overnight so that clear systems are obtained. Paroxetine HCl (0.5% w/v) was dissolved completely in the above gels. Formulated gels were then stored at 4°C until further evaluation.

Evaluation of in-situ gels

Physico-chemical parameters of Paroxetine HCl in situ gel

The physico-chemical parameters of formulated gels were evaluated for their pH, clarity, and drug content.

Clarity and pH10

The pH of the prepared gel was examined using a digital pH meter (EQ-614A, Equip-Tronics). The pH meter was calibrated before use with standard buffer solutions of pH 4 and 7. Then gel was taken in a beaker, and pH was recorded. The clarity of the gel was determined by the visual inspection method under white and black backgrounds.

Drug content determination11

To determine drug content, 1 mL of each formulation was transferred into a 100 mL volumetric flask and then diluted with distilled water up to the mark. After suitable dilutions, the amount of drug in the formulation was measured by using UV spectroscopy at 293 nm (Shimadzu UV-1800, Japan).

Viscosity determination12

The viscosity of the prepared gel was determined using a Brookfield rheometer (Brookfield DV-I Prime Brookfield Engineering Laboratories. Inc.). The gel was transferred to a 100 mL beaker and maintained at the initial temperature of 10±1oC, and then the rheometer was operated by using a 64 No. spindle at 50 rpm. The temperature was then gradually raised to 10oC to attain the set temperature, and finally, viscosity was noted down.

Mucoadhesive strength determination13

The force required for gel detachment from the tissue of the nasal mucosa is known as mucoadhesive strength. A small piece of the nasal mucosa of prepared gel was used to determine the force required to detach the gel from nasal mucosal tissue. A piece of the nasal mucosa of a sheep was procured from the slaughterhouse at a local market. The mucosa and bone cartilage were separated, and then mucosal tissue was cut into small pieces. With the help of a thread, two pieces of tissue were tied to two separate glass slides. One glass slide was fixed to the bottom of the pan balance with tissue facing the downside. Another slide was fixed on a wooden platform of the balance with tissue facing upwards. Then, 100 mg of prepared gel was placed on the bottom slide, and the upper slide was brought into contact and held for two minutes to ensure tissue contact. Slowly, dummy granules were added to another pan until both tissue slides separated. The mucoadhesive strength of formulations A1 - A5 was measured and, detachment stress was expressed in dyne/cm2 .

Mucoadhesive strength = (m×g)/A×100

Where,

m = weight of granules required to separate the tissues,

g = acceleration due to gravity (980 cm/s2 ),

A = area of mucosa exposed 

In vitro drug release study14

A Franz diffusion cell was used to determine drug release from the gel. Artificial dialysis membrane (Mol wt12,000–14,000 Da) was soaked for 2 h in receptor medium before its use. Around 37 mL of phosphate buffer with pH 7.4 was placed in a receptor compartment. About 2.5 mg of gel, which is equivalent to a drug, was transferred into the donor compartment. Both compartments were separated by an artificial dialysis membrane. Throughout the study, the receptor medium temperature was maintained at 32±1o C. From the receptor compartment, 0.5 mL of the sample was withdrawn at definite time intervals until 8 h and replaced with an equal quantity of fresh buffer every time. The samples were analyzed by UV spectroscopy at 293 nm with suitable dilutions before analysis.

Ex vivo drug permeation evaluation15

The ex vivo permeation study was performed using a similar method as the in vitro study. In this study, artificial dialysis membrane was replaced with the nasal mucosa of the goat, and the duration of the study was 8 h. Freshly sacrificed nasal mucosa from the goat was collected from a slaughter shop at a local market and was immediately transferred into saline phosphate buffer of pH 7.4. The nasal septum was separated carefully from the bone to obtain mucus membrane and then washed thoroughly with saline phosphate buffer, pH 7.4.

Stability studies

Stability of gels was determined by keeping samples in glass vials and packed with aluminum foil to maintain air-tight conditions and samples were stored at 5°C ± 3°C for one month. After one month, samples were evaluated for drug content, gelation temperature, and physical characteristics.

Results

Gelation temperature determination

A visual inspection method was used to determine gelation temperature, and the results are presented in Table 2. A minimum concentration, i.e., 19% w/v of poloxamer 407 was required for the conversion of sol-gel at 32-34º C. About 0.3% w/v of carbopol 934P was found to be optimum for the mucoadhesive property of the gel. As the concentration of poloxamer 407 increased, the gelling temperature was found to have decreased. The higher concentration of polymer increased the swelling network structures that form gel at lower temperatures. Further addition of carbopol has decreased the gelling temperature, which could be attributed to its highly cross-linked polymeric network structure that gets hydrated and swells in the presence of water.

Drug content determination

The drug content of all the gels was determined by UV spectrophotometer and results were found to be in the range of 96.50 and 98.66%.

Viscosity determination

The viscosity of all the gels was determined using a Brookfield rheometer and the graphical presentation is shown in Figure 1.

Mucoadhesive strength determination

The detachment stress method was adopted to determine mucoadhesive strength, and the results are presented in Table 3. Formulations A2 to A5 have shown sufficient mucoadhesive strength ranging between 5,080.35 to 10,875.82 dynes/cm2 , and the graphical representation is shown in Figure 2.

In vitro drug release study

The Franz diffusion cell and artificial dialysis membrane were used to determine drug release from the gel. Formulations A1 and A4 showed 86% and 87.13% drug release in 8 h, respectively, as presented in Table 4, and a graphical representation of this is shown in Figure 3. Thus, formulation A4 was selected as the optimized formulation for further ex vivo studies.

Ex vivo drug permeation evaluation

Franz diffusion cell and goat's nasal mucus membrane were used in ex vivo permeation study for optimized A4 formulation. The drug permeation of formulation A4 was found to be 82.3% for 8 h, and the results are presented in Table 5 and a graphical representation is shown in Figure 4.

Stability studies

Stability of gels was determined after one month, and samples were evaluated for various parameters like drug content, gelation temperature, and clarity. All formulations showed no change in gelation temperature. The drug content of all formulations was found to be in the range of 95 to 98.64%. All the formulations were found to be clear except A5. The formulation A5 was found to be opaque. The highest concentration of carbopol 934P in A5 may have resulted the density differences and changes in gel network structure, which is responsible for the opacity of the concerned formulation.

Discussion

The preliminary step in thermoreversible gel formulation is to determine the phase transition temperature. It is the temperature at which any system changes its form from one phase to another. In the case of thermoreversible gel, it is the conversion of sol to gel and vice versa. 

The thermoreversible gel should have a phase transition temperature between 25-34oC. If it is below 25oC, it may create issues for handling during manufacturing, and if it is above 34oC, then it may retain its sol state at body temperature and wash away from the nasal cavity after installation. The results have indicated that 19% w/v poloxamer 407 solutions have a gelling temperature of 32-34oC. The concentration below this did not showing any gelling. The negative coefficient of solubility of the block polymer of poloxamer 407 is responsible for its thermoreversible property. The rise in temperature results in an increase in micelle formation which gets tightly bound to form a gel. The addition of carbopol 934P has further decreased the transition temperature due to its gelling property.16-17 Thus, based on the results obtained, 19% w/v poloxamer 407 and 0.3% w/v carbopol 934P were considered as optimized concentrations for the final formulation. The mucoadhesive property of carbopol 934P is associated with the presence of carboxylic groups in its structure. These groups form hydrogen bonds with sugar residue in oligosaccharide chains in mucus membrane, thus showing mucoadhesion. The mucoadhesive strength was found to increase with an increase in carbopol 934P concentration. It is obvious as the rise in concentration results in a rise in carboxylic groups which further increases hydrogen bonding and mucoadhesion.18 During ex vivo drug permeation studies, it was observed that drug permeation was slower for the initial 2 h (< 15%), but it increased significantly after 2 h (> 80% at 8 h). This is associated with the conformational changes in the polymer chain of carbopol resulting in relaxation of the gel network. Further swelling of the block polymer chain results in the relaxation of the gel network and increased permeation after 2 h.19 The formulations were found to be stable concerning to studied parameters.

Conclusion

The developed thermoreversible mucoadhesive in situ intranasal gel of Paroxetine HCl has shown increased residence time in the nasal cavity. Based on the results of in vitro and ex vivo studies, the A4 formulation was found to be optimum. Thus, the present work concluded that Paroxetine HCl in situ intranasal gel is safe as well as effective for treating depression.

Conflict of interest

None

Supporting File
References
  1. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 2019;6(7):601-9.
  2. Glahn DC, Curran JE, Winkler AM, Carless MA, Kent Jr JW, Charlesworth JC, et al. High dimensional endophenotype ranking in the search for major depression risk genes. Biol Psychiatry 2012;71(1):6-14.
  3. Panek M, Kawalec P, Pilc A, Lasoń W. Developments in the discovery and design of intranasal antidepressants. Expert Opin Drug Discov 2020;15(10):1145-64.
  4. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus 2018;16(4):420-9.
  5. Foster RH, Goa KL. Paroxetine. CNS Drugs 1997;8(2):163–88.
  6. Salama HA, Mahmoud AA, Kamel AO, Hady MA, Awad GA. Phospholipid based colloidal poloxamer– nanocubic vesicles for brain targeting via the nasal route. Colloids Surf B Biointerfaces 2012;100:146- 54. 
  7. Lochhead JJ, Throne RG. Drug delivery to the brain. AAPS Adv Pharm Sci Series 2014;10:401–31.
  8. Choi HG, Oh YK, Kim CK. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int J Pharm 1998;165(1):23-32.
  9. Schmolka IR. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res 1972;6(6):571-82.
  10. 10. Tuğcu-Demiröz F, Acartürk F, Erdoğan D. Development of long-acting bioadhesive vaginal gels of oxybutynin: Formulation, in vitro and in vivo evaluations. Int J Pharm 2013;457(1):25-39.
  11. Bhandwalkar MJ, Avachat AM. Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation. AAPS Pharm Sci Tech 2013;14(1):101– 10.
  12. Harish NM, Prabhu P, Charyulu RN, Gulzar MA, Subrahmanyam EV. Formulation and evaluation of in situ gels containing clotrimazole for oral candidiasis. Indian J Pharm Sci 2009;71(4):421-7.
  13. Shah RA, Mehta MR, Patel DM, Patel CN. Design and optimization of mucoadhesive nasal in situ gel containing sodium cromoglycate using factorial design. Asian J Pharm 2011;5(2):65-74.
  14. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 2010;12(3):263-71. 
  15. Javia A, Thakkar H. Intranasal delivery of tapentadol hydrochloride–loaded chitosan nanoparticles: Formulation, characterization and its in vivo evaluation. J Microencapsul 2017;34(7):644-58.
  16. Shelke S, Shahi S, Jalalpure S, Dhamecha, D. Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: Formulation, optimization, evaluation and permeation studies. J Liposome Res 2016;26:313– 23.
  17. Zahir-Jouzdani F, Wolf JD, Atyabi F, Bernkop-Schnürch A. In situ gelling and mucoadhesive polymers: Why do they needeach other? Expert Opin Drug Deliv 2018;15:1007-19.
  18. Nair AB, Chaudhary S, Shah H, Jacob S, Mewada V, Shinu P, et al. Intranasal delivery of darunavir loaded mucoadhesive in situ gel: Experimental design, in vitro evaluation, and pharmacokinetic studies. Gels 2022;8(6):342-65.
  19. Cao F, Zhang X, Ping Q. New method for ophthalmic delivery of azithromycin by poloxamer/ carbopol-based in situ gelling system. Drug Deliv 2010;17(7):500-7
HealthMinds Logo
RGUHS Logo

© 2024 HealthMinds Consulting Pvt. Ltd. This copyright specifically applies to the website design, unless otherwise stated.

We use and utilize cookies and other similar technologies necessary to understand, optimize, and improve visitor's experience in our site. By continuing to use our site you agree to our Cookies, Privacy and Terms of Use Policies.